Sort   by:  
 Page size 
UnknownGenomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models.
Not available
S-EPMC9802478 | biostudies-literature
UnknownIntravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.
Not available
S-EPMC10600726 | biostudies-literature
UnknownInvestigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship.
Not available
S-EPMC2675137 | biostudies-literature
Unknown'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Not available
S-EPMC7320935 | biostudies-literature
UnknownEffect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8491132 | biostudies-literature
UnknownEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Not available
S-EPMC7787219 | biostudies-literature
UnknownSARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
Not available
S-EPMC9762734 | biostudies-literature
UnknownEculizumab improves fatigue in refractory generalized myasthenia gravis.
Not available
S-EPMC6620379 | biostudies-literature
UnknownLong-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Not available
S-EPMC6619057 | biostudies-literature
UnknownPost-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
Not available
S-EPMC7905790 | biostudies-literature
Sort   by:  
 Page size